Search giant Google has proved its mettle in almost every field. And now its latest mission is detecting the fatal cancer disease by swallowing a pill.
Google’s latest “moonshot” project involves a pill that is packed with tiny magnetic particles. Insiders say the pill has the potential to travel through the bloodstream of a patient and search for any malignant cells (if any) and send a report of its findings to a sensor device wore by the patient.
The project, which was announced on Tuesday, is the latest effort by the X division of the Google that works on better application of creative technologies in solving big problems.
Google’s X division is also working on some of the firm’s other outlandish projects, such as self-driving cars and special kind of contact lenses that can measure glucose in tears.
Describing the experiment in the early stages, Google said that the microscopic “nanoparticles” present in the pills are coated with antibodies that bind with specific proteins or cells linked with various maladies.
The particles would remain in the bloodstream and send the findings continuously as long as they stay there, said Andrew Conrad, head of life sciences at Google’s X division.
The reporting signals would be received by the wearable sensor that will follow the magnetic fields of the particles in order to track them and collect data on their movement through the body.
“We want to make it simple and automatic and not invasive,” Conrad stresse.
According to Conrad, Google’s latest project aims at proactively monitoring the health of the cancer patient and prevent the disease in spite of just diagnosing the problems.
Meanwhile, Google is also looking for some commercial partners who would effectively launch the product into the market and also handle its practical uses.
Latest posts by Christina Langfold (see all)
- Coral Reef Damage Scares Florida Keys Researchers and Businesses - Jun 26, 2017
- Nike to Slash Global Workforce by 1,400 - Jun 16, 2017
- Scientist Shocked To See Snakes Carry Out Coordinated Attacks - Jun 2, 2017